| QIAGENOn December 24, it was announced that the Board of Directors had completed its strategic review of all acquisition offers, andDeciding Not to Sell at Present Is the Company’s Best Option。
Following the announcement,QiagenThe stock immediately fell by 27.5%.QiagenIt stated that since the news of the company’s potential sale broke on November 13, it had received several offers, but none were satisfactory, including Thermo Fisher Scientific’s previously reported initial bid of $8 billion. This was also the primary reason for terminating the sale process.
After-hours trading,QiagenThe stock fell 27.66% to $30 per share, with a current total market capitalization of approximately $9.4 billion.
To Sell or Not to Sell, QIAGEN “Doesn’t Lose”
On November 13, according to Bloomberg News,DiagnosisIndustry GiantThermo Fisher Scientific（Thermo Fisher）Considering the Acquisition of a Molecular Diagnostics CompanyQiagen，and could potentially become the second-largest acquisition in Thermo Fisher Scientific's history.The primary purpose of the acquisition is to strengthen its molecular diagnostics business.
Subsequently, Qiagen responded to the acquisition rumors, confirming potential acquisition transactions but did not disclose a specific list of companies with acquisition intentions. QIAGEN stated that after receiving several acquisition proposals, the company has begun conducting a strategic evaluation.In November, the EvaluateMedTech website also analyzedQiagenpotential acquirers, including Thermo Fisher Scientific, Siemens Healthineers, Danaher, and Agilent. Analysts predict,The acquisition price is expected to range between $40 and $45 per share, with more optimistic analysts estimating it at around $47–$50.。However, on December 11, Siemens Healthineers CEO Bernd Montag stated in an interview that the acquisition ofQiagenNot interested. The targets Siemens Healthineers is looking for are not those that are profitable in terms of revenue and profit, but rather those that can better help Siemens Healthineers address major global health challenges.
Before the acquisition news broke,QIAGEN’s market capitalization stands at approximately $8 billion, amid a steady stream of bad news.The stock price once dropped to a three-year low of $25.。- October CEOPeer SchatzAnnouncement of Resignation
- Weakness in the Chinese Market in the Third Quarter
- Decided to suspend ongoing next-generation sequencing-related instrument development activities and incur pre-tax restructuring charges of $260 million to $265 million.
Following the “acquisition fever” in November, QIAGEN’s stock price has been on a steady rise.Peaked at $43.16 per share (the year’s high). The current total market capitalization remains 17.5% higher than before the acquisition announcement. It appears that the one-month-long “hot drama”QiagenIt does not seem to be operating at a loss.
AlthoughQiagenThe second half of 2019 was marked by turbulence, yet the company maintained a certain advantage in the molecular diagnostics sector, with approximately 90% of its sales revenue derived from consumables, yielding substantial profits. By 2024, analysts predict that its overall revenue will grow at an annual rate of 8%.
| 
